Drug news

Kadcyla (ado-trastuzumab emtansine) fails Phase II/III trial for HER-2 + advanced gastric cancer- Roche/Immunogen

Read time: 1 mins

Last updated:23rd Oct 2015

Published:23rd Oct 2015

Source: Pharmawand

The Phase II/III GATSBY trial, designed to support a new indication for Kadcyla (ado-trastuzumab emtansine) from Roche + ImmunoGen in second-line treatment of HER2-positive advanced gastric cancer, did not meet its primary endpoint, the drug’s co-developer ImmunoGen disclosed in a 68-word regulatory filing with the US Securities and Exchange Commission. The filing did not detail how the trial failed.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news

CHMP positive recommendation to change to marketing authorisation of Triumeq (abacavir sulfate / dolutegravir sodium / lamivudine) to treat HIV infections.-ViiV HealthCare

1 mins

Drug news

CHMP positive recommendation to change the marketing authorisation of Sirturo (bedaquiline) in patients with pulmonary tuberculosis.- Jansssen- Cilag (J&J)

On 25 April 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending a change to the terms of the marketing authorisation for the medicinal product Sirturo (bedaquiline). The marketing authorisation holder for this medicinal product is Janssen-Cilag International NV.

1 min

Drug news

CHMP positive recommendation to extend the marketing authorisation of Alecensa (alectinib hydrochloride).- Roche.

1 min

See all news